We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

338:HKEXSinopec Shanghai Petrochemical Co. Ltd. Class H Analysis

Data as of 2026-06-10 - not real-time

₩13,100.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Y‑Biologics is trading well under its short‑term moving averages, with price below both the 20‑day and 50‑day SMA, and the 14‑day RSI indicates a deep oversold condition. The MACD histogram is negative and the signal line is bearish, reinforcing a downward technical bias.
Fundamentally, the company reports negative operating and profit margins, a substantial operating loss, and a large negative free cash flow, while carrying a high debt‑to‑equity ratio and a price‑to‑sales multiple that far exceeds the industry average. Although the sector is in an extreme greed phase, the lack of earnings, zero dividend and a weak balance sheet suggest the current valuation is not justified by the underlying financial health.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price below key moving averages
  • Bearish MACD and deep oversold RSI
  • Negative operating cash flow and high debt

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from clinical pipeline if trials succeed
  • Continued financial losses and cash burn
  • Volatile price action with stable but modest volume

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Long‑term growth prospects in immuno‑oncology
  • Large cash reserves relative to market cap
  • Industry tailwinds for biotech innovation

Key Metrics & Analysis

Financial Health

Revenue Growth-30.80%
ROE-221.97%
ROA-18.45%
Debt/Equity69.72
Op. Cash Flow₩-6509573120
Free Cash Flow₩-7027488256
Industry P/E24.9

Technical Analysis

TrendNeutral
RSI17.2
Support₩12,710.00
Resistance₩21,700.00
MA 20₩17,493.00
MA 50₩22,162.00
MA 200₩21,561.35
MACDBearish
VolumeStable
Fear & Greed Index85.95

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.05
Volatility40.83%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.